News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bruker Corporation Announces AVANCE™-IVDr as a Standardized NMR Platform for Clinical Screening and In Vitro Diagnostics (IVD) Discovery and Validation



7/22/2013 9:43:24 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KARLSRUHE, Germany--(BUSINESS WIRE)--Bruker today announces a standardized nuclear magnetic resonance (NMR) spectroscopy platform for its clinical and diagnostics partners that enables cost-effective, high-performance NMR clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays. The new AVANCE-IVDr system, presently for research use only, is a complete, proven and standardized platform for NMR clinical research and screening, as well as for IVD-by-NMR research. It features high sensitivity and information-rich output at 600 MHz proton-NMR frequency, and incorporates advanced hardware, software, automation, spectral libraries and standard operating procedures (SOPs) for high-performance bio-fluid screening and assay validation. Customer benefits include higher information content and spectral feature differentiation compared to low-field NMR systems, as well as excellent reproducibility, high throughput and potentially dramatically lower cost per sample for better clinical screening and IVD-by-NMR.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES